468 RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study

Схожие документы

• 1657 Who Seeks a Fecal Microbiota Transplant for Recurrent C. difficile Infection?: Patient Profile of the PUNCH CD Study
  по: Orenstein, Robert, et al.
  Опубликовано: (2014)
• 1799 Next Generation Fecal Transplant for Recurrent C. difficile Infection with and without Antiobiotic Pre-Treatment: Lessons Learned from the PUNCH CD Phase 2 Safety Study
  по: Mariani, Paul, et al.
  Опубликовано: (2014)
• 1950. Prevention of Recurrent Clostridium difficile at Six Months Following Treatment With Microbiota-Based Therapy RBX2660: Durability Results From a Phase 2 Open-Label Study
  по: Mische, Sarah, et al.
  Опубликовано: (2018)
• 669. Twelve-Month Durability of Microbiota-Based Therapy RBX2660 for Prevention of Recurrent Clostridium difficile Infection
  по: Jones, Courtney, et al.
  Опубликовано: (2019)
• 670. VRE Clearance in Patients with Recurrent Clostridium difficile Infection Following Treatment with Microbiota-Based Drug RBX2660
  по: Hau, Heidi, et al.
  Опубликовано: (2019)